Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal, Pierre Fontanillas, Jason A. Flannick, Alisa Knodle Manning, Peter V. Grauman, Brenton G. Mar, Robert Coleman Lindsley, Craig H. Mermel, Noël P. Burtt, Alejandro Chavez, John M. Higgins, Vladislav Moltchanov, Frank C. Kuo, Michael Kluk, Brian E. Henderson, Leena Kinnunen, Heikki A. Koistinen, Claes Ladenvall, Gad A. Getz, Adolfo Correa, Benjamin F. Banahan, Stacey Gabriel, Sekar Kathiresan, Heather M. Stringham, Mark I. McCarthy, Michael Boehnke, Jaakko Tuomilehto, Christopher Haiman, Leif Groop, Gil Atzmon, James G. Wilson, Donna S Neuberg, David Altshuler, Benjamin L. Ebert
New England Journal of Medicine · 2014 · 4,978 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Jaiswal, S., Fontanillas, P., Flannick, J. A., Manning, A. K., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N. P., Chavez, A., Higgins, J. M., Moltchanov, V., Kuo, F. C., Kluk, M., Henderson, B. E., Kinnunen, L., Koistinen, H. A., Ladenvall, C., Getz, G. A., … Ebert, B. L. (2014). Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine, 371(26), 2488–2498. https://doi.org/10.1056/nejmoa1408617
In text: (Jaiswal et al., 2014)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: The incidence of hematologic cancers increases with age. These cancers are associated with recurrent somatic mutations in specific genes. We hypothesized that such mutations would be detectable in the blood of some persons who are not known to have hematologic disorders. METHODS: We analyzed whole-exome sequencing data from DNA in the peripheral-blood cells of 17,182 persons who were unselected for hematologic phenotypes. We looked for somatic mutations by identifying previously characterized single-nucleotide variants and small insertions or deletions in 160 genes that are recurrently mutated in hematologic cancers. The presence of mutations was analyzed for an association with hematologic phenotypes, survival, and cardiovascular events. RESULTS: Detectable somatic mutations were rare in persons younger than 40 years of age but rose appreciably in frequency with age. Among persons 70 to 79 years of age, 80 to 89 years of age, and 90 to 108 years of age, these clonal mutations were observed in 9.5% (219 of 2300 persons), 11.7% (37 of 317), and 18.4% (19 of 103), respectively. The majority of the variants occurred in three genes: DNMT3A, TET2, and ASXL1. The presence of a somatic mutation was associated with an increase in the risk of hematologic cancer (hazard ratio, 11.1; 95% confidence interval [CI], 3.9 to 32.6), an increase in all-cause mortality (hazard ratio, 1.4; 95% CI, 1.1 to 1.8), and increases in the risks of incident coronary heart disease (hazard ratio, 2.0; 95% CI, 1.2 to 3.4) and ischemic stroke (hazard ratio, 2.6; 95% CI, 1.4 to 4.8). CONCLUSIONS: Age-related clonal hematopoiesis is a common condition that is associated with increases in the risk of hematologic cancer and in all-cause mortality, with the latter possibly due to an increased risk of cardiovascular disease. (Funded by the National Institutes of Health and others.).
Related papers
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summary2021
- Hallmarks of Cancer: New Dimensions2022
- Comprehensive molecular characterization of human colon and rectal cancer2012
- p53 Mutations in Human Cancers1991
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer2015
Metadata from OpenAlex (CC0). Citations are generated from the published record.